55579-99-2

Basic information

• Product Name: 4-(4-METHOXYPHENOXY)BUTANOIC ACID
• Synonyms: 4-(4-Methoxyphenoxy)butanoic acid; butanoic acid, 4-(4-methoxyphenoxy)-
• CAS NO: 55579-99-2
• Molecular Formula: C₁₁H₁₄O₄
• Molecular Weight: 210.23
• Product Categories: Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 55579-99-2.mol

Chemical Properties

• Boiling Point: 394.4°Cat760mmHg
• Flash Point: 155°C
• Appearance: /
• Density: 1.157g/cm³
• Vapor Pressure: 6.29E-07mmHg at 25°C
• Refractive Index: 1.518
• CAS DataBase Reference: 4-(4-METHOXYPHENOXY)BUTANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-METHOXYPHENOXY)BUTANOIC ACID(55579-99-2)
• EPA Substance Registry System: 4-(4-METHOXYPHENOXY)BUTANOIC ACID(55579-99-2)

Safety Data

• Hazardous Substances Data: 55579-99-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-methoxyphenoxy)butanoic acid is used as a reactant for the preparation of anti-implantation agents. These agents are crucial in the development of contraceptive medications, helping to prevent the implantation of a fertilized egg in the uterus, thus avoiding pregnancy.
4-(4-methoxyphenoxy)butanoic acid is also used as a reactant in the synthesis of hallucinogenic phenethylamines analogs. These analogs have potential applications in the research and development of novel psychoactive substances, which can be used for therapeutic purposes or to better understand the mechanisms of hallucinogenic effects.

InChI:InChI=1/C11H14O4/c1-14-9-4-6-10(7-5-9)15-8-2-3-11(12)13/h4-7H,2-3,8H2,1H3,(H,12,13)

Upstream product

• 20744-05-2 4-(4-methoxyphenoxy)butyric acid ethyl ester 
• 96-48-0 4-butanolide 
• 150-76-5 4-methoxy-phenol 
• 1122-95-8 sodium 4-methoxyphenolate 
• 201486-52-4 1-Indol-1-yl-4-(4-methoxy-phenoxy)-butan-1-one 

Downstream Products

• 55580-00-2 7-methoxy-3,4-dihydro-1-benzoxepin-5(2H)-one 
• 201486-48-8 N-[2-(2,2-Dimethoxy-ethyl)-phenyl]-4-(4-methoxy-phenoxy)-butyramide 
• 206984-91-0 (4S)-4-benzyl-3-[[4'-(4-methoxyphenyl)oxy]butyloyl]-2-oxazolidinone 
• 226903-45-3 diethyl 6-ethoxy-3,6-dihydro-4-[3-(p-methoxyphenoxy)propyl]-2H-thiopyran-2,2-dicarboxylate 
• 226903-50-0 6-ethoxy-3,6-dihydro-4-[3-(p-methoxyphenoxy)propyl]-2H-thiopyran-2,2-dimethanol 
• 226903-40-8 1-[[(Z)-6-ethoxy-4-methylene-5-hexenyl]oxy]-4-methoxybenzene 
• 226903-38-4 (Z)-1-ethoxy-6-(p-methoxyphenoxy)-1-hexen-3-one 
• 226903-32-8 N-methoxy-4-(p-methoxyphenoxy)-N-methylbutyramide 

Relevant articles and documents

Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza- benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists

Combination of structural elements from a potent Y5 antagonist (2) with thiazole fragments that exhibit weak Y5 affinities followed by lead optimisation led to the discovery of (5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen-2-yl)- piperidin-4-ylmethyl-amino and (4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen-2- yl)-piperidin-4-ylmethyl-amino derivatives. Both classes of compounds are capable of delivering potent and selective orally and centrally bioavailable NPY Y5 receptor antagonists.

Substituted tetralins, chromans and related compounds in the treatment of asthma

PCT No. PCT/US87/02734 Sec. 371 Date Apr. 11, 1990 Sec. 102(e) Date Apr. 11, 1990 PCT Filed Oct. 19, 1987Substituted tetralins, chromans and related compounds which, by inhibiting 5-lipoxygenase enzyme and/or blocking leukotriene receptors, are useful in the prevention or treatment of asthma, arthritis, psoriasis, ulcers, myocardial infarction and related disease states in mammals; pharmaceutical compositions comprising said compounds; a method of treatment with said compounds; and intermediates useful in the synthesis of said compounds.

2-(2-aminophenyl)-acetaldehyde dimethyl acetal: A novel reagent for the protection of carboxylic acids

The synthesis and use of 2-(2-aminophenyl)-acetaldehyde dimethyl acetal 1 are described. The amides 2, derived from this amine and carboxylic acids, are stable under basic conditions and thus can be regarded as the protected carboxylic acids. The corresponding carboxylic acids are regenerated by conversion of 2 into indolylamides 3 by treatment with CSA and subsequent hydrolysis with LiOOH or NaOH. In addition, 3 can be easily converted to esters, amides, and aldehydes.

Conformationally Restricted Tetrahydro-1-benzoxepin Analogs of Hallucinogenic Phenethylamines

Tetrahydro-1-benzoxepin analogs of prototypical 4-substituted-2,5-dimethoxyphenylisopropylamines were prepared as agents having restricted conformational mobility in the 2-alkoxy group and alkylamine sidechain. The derivatives were evaluated for their abi

Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases

Substituted tetralins, chromans and related compounds which, by inhibiting 5-lipoxygenase enzyme and/or blocking leukotriene receptors, are useful in the prevention or treatment of asthma, arthritis, psoriasis, ulcers, myocardial infarction and related disease states in mammals, pharmaceutical compositions thereof, a method of treatment therewith, and to intermediates useful in the synthesis thereof.

A New Class of Antiarrhythmic Agents: Mannich Bases of 3,4-Dihydro-1-benzoxepin-5(2H)-ones and Related Compounds

Mannich bases derived from 3,4-dihydro-1-benzoxepin-5(2H)-ones, chromanones and 6,7,8,9-tetrahydrobenzocyclohepten-5(H)-one have been synthesised and shown to possess marked antiarrhythmic activity; 3,4-dihydro-7-methyl-4-(1-piperidinomethyl)- and 3,4-dih